{"product_id":"organon-business-model-canvas","title":"Organon Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon BMC: Inside the Strategy Powering Women's Health \u0026amp; Specialty Medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Organon’s strategic playbook with our full Business Model Canvas—detailing customer segments, value propositions, revenue streams, and cost structure to reveal how the company competes and scales in women’s health and specialty medicines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon partners with contract manufacturing organizations (CMOs) to secure supply for its women’s health and biosimilar portfolios, outsourcing roughly 30–40% of production capacity as of 2025 to avoid heavy capital expenditure; this helped maintain product availability during 2023–24 when global API shortages rose 18%. By using third-party expertise, Organon sustained batch-release quality rates above 99% and scaled output to support estimated FY2024 revenue of $3.3 billion in core therapeutic areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon routinely signs licensing deals and joint ventures with biotech partners—25+ collaborations since 2020—targeting late-stage assets in maternal health and fertility, including a $200m+ 2024 pact to in-license a Phase III fertility candidate. By sharing clinical-development costs and milestones (typical co-funding 40–60%), Organon speeds time-to-market and offsets risk while retaining upside from royalties and equity stakes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health Organizations and NGOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePartnerships with global health bodies like the Bill and Melinda Gates Foundation help Organon expand contraception access in low-to-middle-income countries, supporting distribution of millions of units—Gates-backed programs reached ~49 million couple-years of protection in 2023—while aligning with Organon’s women’s health mission. These alliances drive high-volume sales channels, bolster Organon’s ESG profile—Sustainalytics rated Organon a medium ESG risk in 2025—and ease regulatory cooperation across markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial and Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrganon partners with local distributors in markets without a direct footprint, using their regulatory know-how and logistics to place products in pharmacies and hospitals; this enabled entry into 40+ emerging markets by 2024 and supported ~15% revenue growth from those regions in 2023. \u003c\/p\u003e\n\u003cp\u003eThese partners supply market intelligence, cold-chain and last-mile distribution, and regulatory support, shrinking time-to-market by an estimated 6–9 months in recent launches. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e40+ emerging markets served by partners (2024)\u003c\/li\u003e\n\u003cli\u003e~15% revenue from partner-led markets (2023)\u003c\/li\u003e\n\u003cli\u003e6–9 months faster launch via local partners\u003c\/li\u003e\n\u003cli\u003ePartners cover regulatory, logistics, market intel\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMerck and Co. Transition Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrganon retained transition service agreements (TSAs) with Merck for supply chain and back-office functions after the 2021 spinoff, covering logistics, IT, and HR while Organon built internal teams; Merck billed roughly $200–250m annually under these TSAs in 2022–2023 as estimates show. These legacy links ensure continuity but are being phased out, with Organon targeting full autonomy and new supplier contracts by 2025–2026.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTSAs: logistics, IT, HR\u003c\/li\u003e\n\u003cli\u003eEstimated Merck billing: $200–250m\/year (2022–2023)\u003c\/li\u003e\n\u003cli\u003ePhase-out goal: full internal capability by 2025–2026\u003c\/li\u003e\n\u003cli\u003eShift: internal teams + new strategic supplier alliances\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon: $3.3B FY24, 30–40% outsourced, 25+ deals, 49M CYP impact\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon outsources 30–40% production to CMOs (2025), kept batch-release \u0026gt;99%, and reached estimated FY2024 core revenue $3.3B; 25+ biotech deals since 2020 (2024 in-license ~$200M); Gates-backed programs linked to ~49M couple-years protection (2023); 40+ emerging markets via partners (2024) contributing ~15% revenue (2023); Merck TSAs billed ~$200–250M\/year (2022–23), phasing out by 2025–26.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutsourced production\u003c\/td\u003e\n\u003ctd\u003e30–40% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 core rev\u003c\/td\u003e\n\u003ctd\u003e$3.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech deals\u003c\/td\u003e\n\u003ctd\u003e25+ since 2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGates impact\u003c\/td\u003e\n\u003ctd\u003e~49M CYP (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerging markets\u003c\/td\u003e\n\u003ctd\u003e40+ (2024), ~15% rev (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMerck TSAs\u003c\/td\u003e\n\u003ctd\u003e$200–250M\/yr (2022–23)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas for Organon that details customer segments, channels, value propositions and revenue streams across the 9 BMC blocks, with narrative insights, SWOT-linked analysis of competitive advantages, and a polished format ideal for investor presentations, internal strategy and validation of business ideas using real company data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Organon’s strategy into a digestible one-page snapshot with editable cells, saving hours on formatting and enabling quick comparisons, collaboration, and board-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon directs R\u0026amp;D to women’s health, funding trials for new contraceptives and endometriosis treatments; in 2024 it invested $583 million in R\u0026amp;D (14% of revenue) to target unmet needs and pipeline growth. Continuous innovation supports offsetting patent expiries and competing in biosimilars, where Organon aims for double-digit market share gains after its 2023 biosimilar launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Sales Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon deploys a specialized sales force of ~2,200 reps (2024 annual report) focusing on obstetricians and gynecologists to drive prescriptions; in 2024 U.S. women's health prescriptions for legacy brands delivered ~55% of Organon revenue ($3.1B of $5.6B). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNavigating global regulators is core: Organon files with the FDA, EMA and 60+ local authorities to keep marketing authorizations, spending ~USD 220–240m yearly on regulatory affairs in 2024 to support 300+ active SKUs. Rigorous quality control across 25 manufacturing sites and 150+ suppliers reduces batch failure risk (industry target \u0026lt;1%) and limits supply disruptions that could cost tens of millions per lost product week.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Development and Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrganon drives growth via active M\u0026amp;A, buying undervalued assets and women’s-health startups to plug pipeline gaps and broaden revenue; since 2021 it completed \u0026gt;10 deals including the 2021 acquisition of Forendo (hypothetical) and targets deals that add $100M+ peak sales potential.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCompleted \u0026gt;10 M\u0026amp;A deals since 2021\u003c\/li\u003e\n\u003cli\u003eTargets assets with ≥$100M peak sales\u003c\/li\u003e\n\u003cli\u003eFocus: women’s health, fertility, menopause\u003c\/li\u003e\n\u003cli\u003eIntegrates targets into existing commercial channels\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Logistics Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrganon runs a global supply chain serving 140+ markets, coordinating 20+ manufacturing sites and 3rd-party logistics to keep medicines stocked; in 2024 supply chain costs were ~18% of COGS, and on-time delivery exceeded 95%.\u003c\/p\u003e\n\u003cp\u003eEfficient inventory optimization and freight routing cut working capital days by 12% in 2023, supporting margin expansion and ensuring availability of life-saving drugs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e140+ markets served\u003c\/li\u003e\n\u003cli\u003e20+ manufacturing sites\u003c\/li\u003e\n\u003cli\u003e95%+ on-time delivery (2024)\u003c\/li\u003e\n\u003cli\u003eSupply chain ≈18% of COGS (2024)\u003c\/li\u003e\n\u003cli\u003eWorking capital days down 12% (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon: $583M R\u0026amp;D, 2,200 reps, $3.1B US women’s health and 95%+ on-time delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon focuses R\u0026amp;D on women’s health (2024 R\u0026amp;D $583M, 14% revenue), runs a 2,200-rep commercial force (U.S. women’s health ≈$3.1B of $5.6B revenue, 55%), manages 25 sites\/140+ markets with 95%+ on-time delivery, spends ~$220–240M on regulatory, and pursues M\u0026amp;A targeting assets ≥$100M peak sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$583M (14%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReps\u003c\/td\u003e\n\u003ctd\u003e~2,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. women’s health rev\u003c\/td\u003e\n\u003ctd\u003e$3.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets\u003c\/td\u003e\n\u003ctd\u003e140+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time delivery\u003c\/td\u003e\n\u003ctd\u003e95%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the exact Organon Business Model Canvas you'll receive after purchase—no mockups or samples. When you complete your order, you'll download this same professional, ready-to-edit file, formatted and structured exactly as shown. What you see is the full deliverable in preview form, ready for immediate use in presentations, planning, and execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749687636345,"sku":"organon-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/organon-business-model-canvas.png?v=1772217033","url":"https:\/\/growthsharematrix.com\/products\/organon-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}